Bifeprunoks

Bifeprunoks
(IUPAC) ime
	7-[4-(bifenil-3-ilmetil)piperazin-1-il]-1,3-benzoksazol-2(3H)-on
Klinički podaci
Identifikatori
CAS broj	350992-10-8
ATC kod	nije dodeljen
PubChem	208951
ChemSpider	181044
UNII	AP69E83Z79
ChEMBL	CHEMBL218166
Hemijski podaci
Formula	C24H23N3O2
Mol. masa	385,458 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28) ; Key: CYGODHVAJQTCBG-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Bifeprunoks (DU-127,090) je atipični antipsihotik. On zajedno sa SLV313, aripiprazolom, i SSR-181507 poseduje kombinaciju minimalnog agonizma za D₂ receptor i 5-HT agonizma.^[5]

Mehanizam dejstva bifeprunoksa se razlikuje od konvencionalnih tipičnih i atipičnih antipsihotika. Tipični antipsihotici, poput hlorpromazina i haloperidola su potentni D₂ antagonisti. Atipični antipsihotici počevši od klozapina, koji su klasifikovani kao multireceptorka jedinjenja, deluju kao agonisti na 5-HT_1A i antagonisti na D₂ receptorima. Bifeprunoks i drugi noviji atipični antipsihotici umesto toga su antagonisti D₂ receptora, i deluju kao parcijalni agonisti kao i antagonisti na 5-HT_1A receptorima.^[6]

Chemistry

Jedan od mogućih sintetičkih puteva je:^[7]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Cuisiat S, Bourdiol N, Lacharme V, Newman-Tancredi A, Colpaert F, Vacher B (2007). „Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities”. J. Med. Chem. 50 (4): 865–76. DOI:10.1021/jm061180b. PMID 17300168.
↑ Bardin L, Auclair A, Kleven MS, et al. (2007). „Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics”. Behav Pharmacol 18 (2): 103–18. DOI:10.1097/FBP.0b013e3280ae6c96. PMID 17351418.
↑ Feenstra, R. W.; de Moes, J.; Hofma, J. J.; Kling, H.; Kuipers, W.; Long, S. K.; Tulp, M. T. M.; van der Heyden, J. A. M.; Kruse, C. G.; Bioorg. Med. Chem. Lett. (2001). New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2-receptor and serotonin 5-HT1A-receptor affinities. 11. pp. 2345.. DOI:10.1016/S0960-894X(01)00425-5.

Povezano

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[5] Cuisiat S, Bourdiol N, Lacharme V, Newman-Tancredi A, Colpaert F, Vacher B (2007). „Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities”. J. Med. Chem. 50 (4): 865–76. DOI:10.1021/jm061180b. PMID 17300168.

[6] Bardin L, Auclair A, Kleven MS, et al. (2007). „Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics”. Behav Pharmacol 18 (2): 103–18. DOI:10.1097/FBP.0b013e3280ae6c96. PMID 17351418.

[7] Feenstra, R. W.; de Moes, J.; Hofma, J. J.; Kling, H.; Kuipers, W.; Long, S. K.; Tulp, M. T. M.; van der Heyden, J. A. M.; Kruse, C. G.; Bioorg. Med. Chem. Lett. (2001). New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2-receptor and serotonin 5-HT1A-receptor affinities. 11. pp. 2345.. DOI:10.1016/S0960-894X(01)00425-5.

[1]

[2]

[3]

[4]

[5]

[6]

[7]